AstraZeneca PLC Director/PDMR Shareholding (1296I)

TIDMAZN

RNS Number : 1296I

AstraZeneca PLC

31 March 2020

31 March 2020 07:00 BST

Transactions by Persons Discharging Managerial Responsibilities

Disclosure under Article 19 of the EU Market Abuse Regulation

AstraZeneca PLC (the Company) announced that, on 27 March 2020, awards of the Company's ordinary shares of $0.25 each (Ordinary Shares) vested to certain Persons Discharging Managerial Responsibilities of the Company (PDMRs) under the AstraZeneca Performance Share Plan (AZPSP).

The AZPSP award was granted on 27 March 2015 and was subject to a three-year performance period followed by a two-year holding period before vesting. Application of the performance measures specified at the time of grant resulted in 77% of the AZPSP award vesting and the remaining unvested part lapsing.

Following the withholding of shares to satisfy certain tax obligations arising on vesting, the PDMRs' beneficial interests in Ordinary Shares changed as detailed in the table below:

 
 PDMR                 Ordinary Shares 
                   acquired under the 
                                AZPSP 
 Pascal Soriot                 74,698 
                 -------------------- 
 Marc Dunoyer                  19,429 
                 -------------------- 
 

For tax purposes, the fair market value of an Ordinary Share at vest was 6882 pence, being the closing price on the last trading day preceding the vesting.

Further details are set out in the attached notifications, made in accordance with the requirements of the EU Market Abuse Regulation.

 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        Pascal Soriot 
     --------------------------  ------------------------------------------------ 
 2    Reason for the notification 
     ---------------------------------------------------------------------------- 
 a)   Position/status             Chief Executive Officer 
     --------------------------  ------------------------------------------------ 
 b)   Initial notification        Initial notification 
       /Amendment 
     --------------------------  ------------------------------------------------ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------------- 
 a)   Name                        AstraZeneca PLC 
     --------------------------  ------------------------------------------------ 
 b)   LEI                         PY6ZZQWO2IZFZC3IOL08 
     --------------------------  ------------------------------------------------ 
 4i   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of US$0.25 each in 
       financial instrument,       AstraZeneca PLC 
       type of instrument 
 
       Identification code         GB0009895292 
     --------------------------  ------------------------------------------------ 
 b)   Nature of the transaction   Acquisition of ordinary shares pursuant 
                                   to a vesting under the AstraZeneca 
                                   Performance Share Plan, for nil consideration. 
     --------------------------  ------------------------------------------------ 
 c)   Price(s) and volume(s)        Price(s)   Volume(s) 
                                     0          74,698 
                                               ---------- 
     --------------------------  ------------------------------------------------ 
 d)   Aggregated information      Not applicable - single transaction 
 
       - Aggregated volume 
       - Price 
     --------------------------  ------------------------------------------------ 
 e)   Date of the transaction     27 March 2020 
     --------------------------  ------------------------------------------------ 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  ------------------------------------------------ 
 
 
 1    Details of the person discharging managerial responsibilities 
       / person closely associated 
 a)   Name                        Marc Dunoyer 
     --------------------------  ------------------------------------------------ 
 2    Reason for the notification 
     ---------------------------------------------------------------------------- 
 a)   Position/status             Chief Financial Officer 
     --------------------------  ------------------------------------------------ 
 b)   Initial notification        Initial notification 
       /Amendment 
     --------------------------  ------------------------------------------------ 
 3    Details of the issuer, emission allowance market participant, 
       auction platform, auctioneer or auction monitor 
     ---------------------------------------------------------------------------- 
 a)   Name                        AstraZeneca PLC 
     --------------------------  ------------------------------------------------ 
 b)   LEI                         PY6ZZQWO2IZFZC3IOL08 
     --------------------------  ------------------------------------------------ 
 4i   Details of the transaction(s): section to be repeated 
       for (i) each type of instrument; (ii) each type of transaction; 
       (iii) each date; and (iv) each place where transactions 
       have been conducted 
     ---------------------------------------------------------------------------- 
 a)   Description of the          Ordinary Shares of US$0.25 each in 
       financial instrument,       AstraZeneca PLC 
       type of instrument 
 
       Identification code         GB0009895292 
     --------------------------  ------------------------------------------------ 
 b)   Nature of the transaction   Acquisition of ordinary shares pursuant 
                                   to a vesting under the AstraZeneca 
                                   Performance Share Plan, for nil consideration. 
     --------------------------  ------------------------------------------------ 
 c)   Price(s) and volume(s)        Price(s)   Volume(s) 
                                     0          19,429 
                                               ---------- 
     --------------------------  ------------------------------------------------ 
 d)   Aggregated information      Not applicable - single transaction 
 
       - Aggregated volume 
       - Price 
     --------------------------  ------------------------------------------------ 
 e)   Date of the transaction     27 March 2020 
     --------------------------  ------------------------------------------------ 
 f)   Place of the transaction    Outside a trading venue 
     --------------------------  ------------------------------------------------ 
 

AstraZeneca

AstraZeneca (LSE/STO/NYSE: AZN) is a global, science-led biopharmaceutical company that focuses on the discovery, development and commercialisation of prescription medicines, primarily for the treatment of diseases in three therapy areas - Oncology, Cardiovascular, Renal and Metabolism, and Respiratory. Based in Cambridge, UK, AstraZeneca operates in over 100 countries and its innovative medicines are used by millions of patients worldwide. Please visit astrazeneca.com and follow the Company on Twitter @ AstraZeneca .

Contacts

For details on how to contact the Investor Relations Team, please click here . For Media contacts, click here .

Adrian Kemp

Company Secretary

AstraZeneca PLC

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHURSWRRWUOOAR

(END) Dow Jones Newswires

March 31, 2020 02:00 ET (06:00 GMT)